The lymphocyte proliferative responses to respiratory syncytial virus (RSV) were evaluated for 10 healthy adult donors and compared with proliferative responses to a chimeric glycoprotein (FG glycoprotein) which consists of the extracellular domains of both the F and G proteins of RSV and which is produced from a recombinant baculovirus. The lymphocytes of all 10 donors responded to RSV, and the proliferative responses to the whole virus were highly correlated with the responses to the FG glycoprotein. These data suggested that one or both of these glycoproteins of RSV were major target structures for stimulation of the human lymphocyte proliferative response among virus-specific memory T cells. The lymphocytes of four donors were evaluated further for their proliferative responses to a nested set of overlapping peptides modeled on the extracellular and cytoplasmic domains of the F protein of RSV. Strikingly, the lymphocytes of all 4 donors responded primarily to a region defined by a single peptide spanning residues 338 to 355, and the lymphocytes of 2 donors responded to an overlapping peptide spanning residues 328 to 342 also, thus defining a region of the F1 subunit within residues 328 to 355 that may circumscribe an immunodominant site for stimulation of human T cells from a variety of individuals. This region of the F protein is highly conserved among A and B subgroup viruses. As revealed by monoclonal antibody blocking studies, the lymphocytes responding to this antigenic site had characteristics consistent with T helper cells. Similar epitope mapping studies were performed with BALB/c mice immunized with the FG protein in which a relatively hydrophobic peptide spanning residues 51 to 65 within the F2 subunit appeared to be the major T cell recognition determinant. The data are discussed with respect to an antigenic map of the F protein and the potential construction of a synthetic vaccine for RSV.

A synthetic peptide modeled on residues 45 to 60 of the 1A protein of respiratory syncytial (RS) virus [1A(45-60)] was constructed and used for immunization of mice and rabbits. The immunoglobulin G fraction of the resulting rabbit antibody, purified on protein A-Sepharose, immunoprecipitated from RS-infected HEp-2 cells a protein with a molecular size of-9.5 kilodaltons, which corresponds to the previously published molecular size of the 1A protein (Y. T. Huang, P. L. Collins, and G. W. Wertz, Virus Res. 2:157-173, 1985). To investigate the T-cell-inducing properties of 1A(45-60), six strains of mice were immunized and their popliteal lymph node cells were tested for proliferation upon restimulation with peptide in vitro. The lymph * Corresponding author.

ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.

This report details the structure‐activity relationships of the HIV gag substrate analog Val‐Ser‐Gln‐Asn‐LeuΨ[CH(OH)CH2]Val‐Ile‐Val (U‐85548E), an inhibitor exhibiting subnanomolar affinity towards HIV type‐1 aspartic proteinase (HIV‐1 PR). Our data show that the P1‐P′2 tripeptidyl sequence provides the minimal chemical determinant for HIV‐1 PR binding. We describe the structure‐activity properties of LeuiΨ[CH(OH)CH2]Val substitution in other peptidyl ligands of nonviral substrate origin (e.g., angiotensinogen, insulin and pepstatin). Furthermore, the aspartic proteinase selectivities of a few key compounds are summarized relative to evaluation against human renin, human pepsin, and the fungal enzyme, rhizopuspepsin. These studies have led to the rational design of nanomolar potent inhibitors of both HIV‐1 and HIV‐2 PR. Finally, a 2.5 Å resolution X‐ray crystallographic structure of U–85548E complexed to synthetic HIV‐1 PR dimer (Jaskolski etal, Biochemistry 30, 1600 [1991]) provided a 3‐D picture of the inhibitor bound to the enzyme active site, and we performed computer‐assisted molecular modeling studies to explore the possible binding modes of the above series of LeuΨ[CH(OH)CH2]Val substituted HIV‐1 PR inhibitors.

The 1A protein of respiratory syncytial (RS) virus is a small, 64-amino acid hydrophobic protein expressed in infected cells. We previously showed that the C-terminal domain of 1A contained a site for stimulation of RS virus-reactive Th lymphocytes in BALB/c and SJL/J mice. In this report we modeled a series of overlapping synthetic peptides of the 1A protein and we present evidence to suggest that the C-terminal domain of the 1A protein contains not one, but two, Th lymphocyte-stimulating sites. Although these sites are extensively overlapping they can be distinguished on the basis of presentation by distinct class II restriction elements of the murine MHC. Additionally, we present evidence to suggest that a 16-amino acid synthetic peptide which contains both of these T cell sites can stimulate T cell activity in mice of multiple different class II MHC haplotypes, perhaps representing a potential lead for designing a "universal" T cell stimulator.